SPOTLIGHT -
NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy
A panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.
Expert Perspectives on Molecular Testing in Non–Small Cell Lung Cancer
Comprehensive discussion on molecular testing strategies utilized in non–small cell lung cancer to help inform treatment decisions.
Case 1: Frontline Treatment of ALK+ NSCLC With Brain Metastases
Shared insight on a patient case of ALK+ non–small cell lung cancer with CNS metastasis and the role of brain MRIs in clinical practice.
Overview on ALK+ Metastatic Non–Small Cell Lung Cancer
Expert panelists open their discussion on ALK+ non–small cell lung cancer and reflect on the impact of CNS metastasis in this setting.
Mechanisms of Resistance to TKI in NSCLC
D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to TKIs in oncogene-driven non–small cell lung cancer.
PROFILE 1007 Trial: Crizotinib vs Pemetrexed or Docetaxel in NSCLC
D. Ross Camidge, MD, PhD, comments on the subgroup analysis of the PROFILE 1007 trial, which looked at crizotinib versus either pemetrexed or docetaxel in NSCLC.
Crizotinib in ROS1 Rearranged NSCLC
D. Ross Camidge, MD, PhD, discusses the potential to utilize crizotinib as a treatment for patients with advanced non-small cell lung cancer who harbor a ROS1 gene rearrange
